Alopecia Areata Treatment Denied: How to Appeal Olumiant and Litfulo

Alopecia areata causes sudden, unpredictable hair loss that can progress to complete scalp or total body hair loss. For decades, no FDA-approved systemic treatments existed. That changed in 2022–2023 with the approvals of Olumiant (baricitinib) and Litfulo (ritlecitinib) — the first-ever FDA-approved systemic treatments specifically for alopecia areata. Despite this historic milestone, many insurance companies continue to deny coverage. Here's how to fight back.

The FDA Approval Argument: Rebutting "Experimental" Denials

If your insurer denied Olumiant or Litfulo by calling them "experimental" or "investigational," this is factually incorrect and your strongest appeal argument:

Olumiant (baricitinib): FDA-approved June 2022 for severe alopecia areata in adults. The approval was based on BRAVE-AA1 and BRAVE-AA2 trials showing 35–39% of patients achieving SALT ≤20 (substantial hair regrowth).

Litfulo (ritlecitinib): FDA-approved June 2023 for severe alopecia areata in adults and adolescents 12 years and older. First approval specifically for adolescents. ALLEGRO trial data supported approval.

Your appeal letter should explicitly cite the FDA approval dates and indication language. Include a statement from your dermatologist confirming that treatment is consistent with the FDA-approved indication.

SALT Scoring: Proving Severity

The SALT (Severity of Alopecia Tool) is the standard severity metric for alopecia areata:

• SALT score 0: No hair loss
• SALT score 100: Complete scalp hair loss (alopecia totalis)
• Severe disease threshold: SALT ≥50 (50% or more scalp hair loss)

The FDA approvals for both Olumiant and Litfulo specify "severe" alopecia areata, generally defined as SALT ≥50. Your dermatologist should document the SALT score at each visit and include it explicitly in Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization documentation.

Beyond SALT, document whether the patient has:

• Alopecia totalis (complete scalp hair loss)
• Alopecia universalis (total body hair loss including eyebrows, eyelashes)
• Duration of current episode and prior episodes
• Prior treatment history (corticosteroid injections, topical minoxidil, anthralin, DNCB)

AAD Guidelines and Evidence Basis

The American Academy of Dermatology (AAD) has published clinical guidelines on alopecia areata that support systemic JAK inhibitor use for severe disease. Reference:

• AAD Clinical Practice Guidelines for Alopecia Areata
• Published clinical trial data from BRAVE-AA1/AA2 and ALLEGRO trials in NEJM and JAMA Dermatology
• Your dermatologist's board certification and fellowship training in hair disorders (if applicable)

NAAF Patient Resources

The National Alopecia Areata Foundation (NAAF, naaf.org) offers patient appeal resources, insurance advocacy guides, and clinical references. NAAF has actively advocated for insurance coverage of Olumiant and Litfulo since their approvals. Reference NAAF's patient access advocacy in your appeal.

Addressing Black Box Warning Concerns

Olumiant and Litfulo are JAK inhibitors and carry class black box warnings (serious infections, malignancies, cardiovascular events, thrombosis). Insurers may use this as an additional denial reason. Your appeal should address this:

• The prescribing dermatologist has reviewed the black box warning and evaluated the patient's individual risk profile
• The FDA approved these medications specifically for alopecia areata after weighing benefit versus risk
• FDA-required REMS programs and monitoring protocols will be followed
• The psychological and quality-of-life burden of severe alopecia areata is clinically significant and warrants treatment despite class-level risk

Documenting Psychological Impact

Severe alopecia areata causes documented psychological harm — anxiety, depression, PTSD, and social isolation. Courts and external appeal reviewers increasingly recognize that psychological impairment from a dermatological condition meets medical necessity criteria. Include in your appeal:

• DLQI (Dermatology Life Quality Index) score
• PHQ-9 or GAD-7 scores if depression or anxiety documented
• Any psychiatric consultations related to hair loss

Fight Back With ClaimBack

ClaimBack can help you draft an alopecia areata appeal with SALT score documentation, FDA approval evidence, and AAD guideline citations that insurers cannot dismiss.

Start your free appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal